RxDoctor Payments DataLook up a doctor →

Joel Schock, MD

Family Medicine · Fargo, NDNPI 1790789576

Payments from drug & device makers

$1,189,945in general payments, 2019–2025

Across 1,162 payments — averaging $1024.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$572K
  • Pfizer$499K
  • Novo Nordisk AS$93K
  • Regeneron$8K
  • AstraZeneca$7K
  • Genentech, Inc.$5K
  • plus $7K from 47 others

What the payments were for

  • Speaking & faculty fees$130%
  • Food & beverage$8,50199%
  • Education$801%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,189,945 in reported general payments places this provider in the 95th percentile of 337 family medicine providers in North Dakota.

See all family medicine providers in North Dakota

Medicare billing

Part B allowed, 2024
$25,219
Medicare patients
119
Services billed
9,558

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban41$36,366
FarxigaDapagliflozin Propanediol35$31,270
OzempicSemaglutide30$28,665
XareltoRivaroxaban21$16,385
MyrbetriqMirabegron27$15,767
MounjaroTirzepatide16$15,245
TrulicityDulaglutide15$14,156
Soliqua 100-33Insulin Glargine/Lixisenatide14$12,097
JardianceEmpagliflozin14$10,744
Spiriva RespimatTiotropium Bromide13$6,325
VascepaIcosapent Ethyl12$5,075
Breo ElliptaFluticasone/Vilanterol12$5,068
Rosuvastatin Calcium192$2,877
Lantus SolostarInsulin Glargine,hum.Rec.Anlog21$2,867
Metoprolol Succinate127$2,614

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$498,879$36,36641 claims
AstraZenecaFarxiga$6,840$31,27035 claims
Lilly USA, LLCMounjaro, Trulicity$620$29,40131 claims
Novo NordiskOzempic$118$28,66530 claims
Boehringer IngelheimJardiance, Spiriva Respimat$291$17,06927 claims
Johnson & JohnsonXarelto$190$16,38521 claims
Astellas Pharma US IncMyrbetriq$287$15,76727 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$548$12,09714 claims
GSKBreo Ellipta$77$5,06812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 337 family medicine providers in North Dakota.

Other family medicine in Fargo

See the full list for North Dakota

Where these figures come from

Is this you, or does something look wrong? →